Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
02 août 2023 08h30 HE | Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the pricing of its public offering of...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
28 juil. 2023 08h30 HE | Adamis Pharmaceuticals Corporation
SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder
26 juin 2023 07h30 HE | Adamis Pharmaceuticals Corporation
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that its wholly owned subsidiary DMK...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
22 juin 2023 07h30 HE | Adamis Pharmaceuticals Corporation
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that Eboo Versi, MD, PhD, CEO of Adamis...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
25 mai 2023 16h26 HE | Adamis Pharmaceuticals Corporation
DMK CEO, Ebrahim (Eboo) Versi, MD, PhD, named CEO and Chairman of the combined companyCombined company will have commercial products and a library of development candidates, including two clinical...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Announces Reverse Stock Split
19 mai 2023 12h00 HE | Adamis Pharmaceuticals Corporation
SAN DIEGO, May 19, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, announced today that it will effect a 1-for-70 reverse...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
15 mai 2023 16h47 HE | Adamis Pharmaceuticals Corporation
SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company focused on developing and commercializing products in...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update
08 mai 2023 16h05 HE | Adamis Pharmaceuticals Corporation
SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
16 mars 2023 16h24 HE | Adamis Pharmaceuticals Corporation
SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company focused on developing and commercializing products in various therapeutic...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
14 mars 2023 16h01 HE | Adamis Pharmaceuticals Corporation
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...